Natus Medical (NASDAQ:NTUS) issued an update on its fourth quarter earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $0.44-0.47 for the period, compared to the Thomson Reuters consensus estimate of $0.47. The company issued revenue guidance of $128-132 million, compared to the consensus revenue estimate of $130.00 million.Natus Medical also updated its Q4 2019
Pre-Market guidance to 0.44-0.50 EPS.

NASDAQ:NTUS opened at $34.02 on Thursday. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of 23.96 and a beta of 0.69. The company’s 50 day moving average is $32.39. Natus Medical has a 52 week low of $22.25 and a 52 week high of $34.89. The company has a debt-to-equity ratio of 0.12, a current ratio of 1.87 and a quick ratio of 1.36.

Natus Medical (NASDAQ:NTUS) last posted its earnings results on Thursday, October 24th. The company reported $0.36 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.38 by ($0.02). The company had revenue of $123.46 million for the quarter, compared to the consensus estimate of $124.75 million. Natus Medical had a negative net margin of 4.71% and a positive return on equity of 10.43%. The firm’s revenue for the quarter was down 5.5% compared to the same quarter last year. During the same period last year, the company posted $0.40 earnings per share. On average, sell-side analysts forecast that Natus Medical will post 1.25 EPS for the current fiscal year.

Several equities analysts have recently issued reports on NTUS shares. Zacks Investment Research downgraded Natus Medical from a hold rating to a sell rating in a research report on Wednesday, January 8th. TheStreet upgraded Natus Medical from a d+ rating to a c- rating in a research report on Monday, September 30th.

In other Natus Medical news, CEO Jonathan Kennedy sold 8,676 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $32.65, for a total value of $283,271.40. Also, VP Dong Chune Christopher Chung sold 14,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $33.67, for a total value of $471,380.00. Over the last quarter, insiders have sold 29,360 shares of company stock valued at $965,465. Insiders own 1.65% of the company’s stock.

Natus Medical Company Profile

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Featured Article: What is a Tariff?

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with's FREE daily email newsletter.